Pfizer Inc (PFE)

[stockguard]

Need more upgrades so I can keep adding at lower price levels:

CFRA RAISES OPINION ON SHARES OF PFIZER INC. TO BUY FROM HOLD
10:39 am ET June 15, 2020 (CFRA)
We are upgrading our view on shares of Pfizer, Inc. after it was selected last week by the U.S. administration as one of the five companies most likely to come up with a Covid-19 vaccine along with Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Moderna (MRNA), and AstraZeneca PLC (AZN). These five companies will be the beneficiaries of additional funds to support the vaccine development and manufacturing efforts. We maintain our target at $41, 13.5x our '21 EPS estimate, slightly below PFE's 5-year historical forward P/E average of 13.7x. We keep our '20 EPS estimate at $2.85 and raise our '21 EPS estimate by $0.07 to $3.03. Following the recent declines for PFE's share price due to a broad market sell-off resulting from investor concerns of a slow recovery and a second wave of Covid-19 infections, we think current levels offer a good entry point with an upside potential above 20% vs. our target price.